| Literature DB >> 30788293 |
Morvarid Irani1, Maryam Hassanzadeh Bashtian1, Talat Khadivzadeh2, Hosein Ebrahimipour3, Seyyed Mohsen Asghari Nekah4.
Abstract
BACKGROUND: The inadequate reporting of cross-sectional studies, as in the case of the prevalence of Congenital Anomaly, could cause challenges in the synthesis of new evidence and make possible mistakes in the creation of public policies. This study was conducted to critically appraise the quality of the articles involving congenital anomaly prevalence in Iranian infants with the STROBE recommendations.Entities:
Keywords: Congenital anomaly; Epidemiology; Iran; Prevalence; STROBE
Year: 2018 PMID: 30788293 PMCID: PMC6379628
Source DB: PubMed Journal: Iran J Public Health ISSN: 2251-6085 Impact factor: 1.429
Fig. 1:Article selection flow chart
Main structures of the articles about the prevalence of congenital anomaly in Iran
| Mashhadi et al ( | 2014 | English | 2004–2012 | Tabriz | rural | Children(live birth) under eight years of age | 22500 |
| Mohammadzadeh et al ( | 2013 | Persian | 2007–2008 | Babol | Urban, rural | Newborn(live birth | 1684 |
| Khoshhal-Rahdar et al ( | 2014 | Persian | 2013–2014 | Dezful | Urban, rural | Newborn(live birth | 4235 |
| Karbasi et al ( | 2009 | English | October 2003 to June 2004 | Babol | Urban, rural | Newborn(live birth and stillbirth) | 4800 |
| Akbarzadeh et al ( | 2008 | Persian | 2006–2007 | Sabzevar | Urban, rural | Newborn(live birth | 7786 |
| Alijahan et al ( | 2013 | Persian | 2010–2011 | Ardabil | Urban, rural | Newborn(live birth | 6868 |
| Hosseini et al ( | 2014 | Persian | 2012 | Sistan | Urban, rural | Newborn(live birth | 1800 |
| Ahmadzadeh et al ( | 2008 | English | 2003–2006 | Ahwaz | Urban, rural | Newborn(live birth | 4660 |
| Masoodpoor et al ( | 2013 | Persian | 2007–2008 | Rafsanjan | Urban, rural | Newborn(live birth | 6089 |
| Tayebi et al ( | 2016 | English | 2008 | Yazd | Urban, rural | Newborn | 1195 |
| Kavianyn et al ( | 2016 | Persian | 2008–2011 | Golestan | Urban, rural | Newborn(live birth | 92420 |
| Jalali et al ( | 2011 | Persian | 2011 | Rasht | Urban, rural | Newborn(live birth | 1824 |
| Sarrafan et al ( | 2011 | Persian | 2006–2007 | Ahvaz | Urban, rural | Newborn(live birth | 5087 |
| Amini Nasab et al ( | 2014 | Persian | 2007–2011 | Birjand | Urban | Newborn(live birth | 22076 |
| Dastgiri et al ( | 2007 | English | 2000–2004 | Tabriz | Urban, rural | Newborn | 1574 |
| Rostamizadeh et al ( | 2017 | English | 2002–2003 | Azarshahr | Urban, rural | Newborn | 4515 |
| Gheshmi et al ( | 2012 | Persian | 2007 | Bandar Abbas | Urban, rural | Newborn(live birth | 7007 |
Number of articles that fulfill each item of the STROBE Statement
| 1a | Indicate the study’s design with a commonly used term in the title or the abstract | 14 (82) | ||
| Title and abstract | 1b | Provide in the abstract an informative and balanced summary of what was found | 16(94) | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 17 (100) | |
| Objectives | 3 | State-specific objectives, including any prespecified hypotheses | 17 (100) | |
| Study design | 4 | Present key elements of study design early in the paper | 13(76) | |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection. | 17 (100) | |
| Participants | 6 | Cross-sectional study: give the eligibility criteria and the sources and methods of selection of participants. | 15(85) | |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. | 15(88) | |
| Data sources/ measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. | 16(94) | |
| Bias | 9 | Describe any efforts to address potential sources of bias. | 1(6) | |
| Study size | 10 | Explain how the study size was arrived at | 13(76) | |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why. | 11(56) | |
| Statistical methods | 12a | Describe all statistical methods, including those used to control for confounding. | 10(60) | |
| 12b | Describe any methods used to examine subgroups and interactions. | 1(6) | ||
| 12c | Explain how missing data was addressed. | 0(0) | ||
| 12d | Cross-sectional study: If applicable, describe analytical methods taking account of sampling strategy | NA | ||
| 12e | Describe any sensitivity analyses. | 1(6) | ||
| Participants | 13a | Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed | 16(94) | |
| 13b | Give reasons for non-participation at each stage. | NA | ||
| 13c | Consider use of a flow diagram. | 0(0) | ||
| Descriptive data | 14a | Give characteristics of study participants (e.g. Demographic, clinical, social) and information on exposures and potential confounders. | 15(85) | |
| 14b | Indicate a number of participants with missing data for each variable of interest. | 0(0) | ||
| Outcome data | 15 | Cross-sectional study: report numbers of outcome events or summary measures. | 17(100) | |
| Main results | 16a | Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for and why they were included. | 16(94) | |
| 16b | Report category boundaries when continuous variables were categorized. | NA | ||
| 16c | If relevant, consider translating estimates of relative risk into absolute risk for a meaningful period. | NA | ||
| Other Analyses | 17 | Report other analyses were done – e.g. Analyses of subgroups and interactions, and sensitivity analyses. | 15(85) | |
| Key results | 18 | Summarize key results with reference to study objectives. | 17 (100) | |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias. | 9(53) | |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence. | 15(85) | |
| Generalizability | 21 | Discuss the generalizability (external validity) of the study results. | 8(46) | |
| Funding | 22 | Give the sources of funding and the role of the funders for the present study and, if applicable, for the original study on which present article is based. | 7(41) |